195 related articles for article (PubMed ID: 25480830)
1. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
Garcia-Manero G; Khoury HJ; Jabbour E; Lancet J; Winski SL; Cable L; Rush S; Maloney L; Hogeland G; Ptaszynski M; Calvo MC; Bohannan Z; List A; Kantarjian H; Komrokji R
Clin Cancer Res; 2015 Mar; 21(5):985-94. PubMed ID: 25480830
[TBL] [Abstract][Full Text] [Related]
2. Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Bachegowda L; Morrone K; Winski SL; Mantzaris I; Bartenstein M; Ramachandra N; Giricz O; Sukrithan V; Nwankwo G; Shahnaz S; Bhagat T; Bhattacharyya S; Assal A; Shastri A; Gordon-Mitchell S; Pellagatti A; Boultwood J; Schinke C; Yu Y; Guha C; Rizzi J; Garrus J; Brown S; Wollenberg L; Hogeland G; Wright D; Munson M; Rodriguez M; Gross S; Chantry D; Zou Y; Platanias L; Burgess LE; Pradhan K; Steidl U; Verma A
Cancer Res; 2016 Aug; 76(16):4841-4849. PubMed ID: 27287719
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
Goldman JW; Rosen LS; Tolcher AW; Papadopoulos K; Beeram M; Shi P; Pitou C; Bell R; Kulanthaivel P; Zhang X; Fink A; Chan EM; Shahir A; Farrington D; Patnaik A
Invest New Drugs; 2018 Aug; 36(4):629-637. PubMed ID: 29196957
[TBL] [Abstract][Full Text] [Related]
4. p38 MAPK in MDS.
Gañán-Gómez I; Bohannan ZS; Garcia-Manero G
Aging (Albany NY); 2015 Jun; 7(6):346-7. PubMed ID: 26081220
[No Abstract] [Full Text] [Related]
5. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
Gupta P; Mulkey F; Hasserjian RP; Sanford BL; Vij R; Hurd DD; Odenike OM; Bloomfield CD; Owzar K; Stone RM; Larson RA;
Invest New Drugs; 2013 Oct; 31(5):1311-20. PubMed ID: 23700288
[TBL] [Abstract][Full Text] [Related]
8. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
[No Abstract] [Full Text] [Related]
9. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
Angevin E; Spitaleri G; Rodon J; Dotti K; Isambert N; Salvagni S; Moreno V; Assadourian S; Gomez C; Harnois M; Hollebecque A; Azaro A; Hervieu A; Rihawi K; De Marinis F
Eur J Cancer; 2017 Dec; 87():131-139. PubMed ID: 29145039
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Bendell JC; Bischoff HG; Hwang J; Reinhardt HC; Zander T; Wang X; Hynes S; Pitou C; Campbell R; Iversen P; Farrington DL; Bell-McGuinn K; Thomas M
Invest New Drugs; 2020 Aug; 38(4):1145-1155. PubMed ID: 31707688
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
Komrokji RS; Raza A; Lancet JE; Ren C; Taft D; Maniar M; Wilhelm F; List AF
Br J Haematol; 2013 Aug; 162(4):517-24. PubMed ID: 23789936
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
[TBL] [Abstract][Full Text] [Related]
14. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.
Komrokji RS; Padron E; Yu D; Fulp WJ; Rodriguez Y; Tinsley S; List AF; Lancet JE
Am J Hematol; 2014 Aug; 89(8):809-12. PubMed ID: 24764152
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.
Santini V; Valcárcel D; Platzbecker U; Komrokji RS; Cleverly AL; Lahn MM; Janssen J; Zhao Y; Chiang A; Giagounidis A; Guba SC; Gueorguieva I; Girvan AC; da Silva Ferreira M; Bhagat TD; Pradhan K; Steidl U; Sridharan A; Will B; Verma A
Clin Cancer Res; 2019 Dec; 25(23):6976-6985. PubMed ID: 31481511
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
Khoury HJ; Garcia-Manero G; Borthakur G; Kadia T; Foudray MC; Arellano M; Langston A; Bethelmie-Bryan B; Rush S; Litwiler K; Karan S; Simmons H; Marcus AI; Ptaszynski M; Kantarjian H
Cancer; 2012 Jul; 118(14):3556-64. PubMed ID: 22139909
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]